Evidence map›Paper›PMID 40961406›Full record

Trial reportJCO precision oncology2025

Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial.

Adam B Weiner, James A Proudfoot, Mamdouh Aker, Michelle Cardenas, Samantha Gonzalez, Eileen Kelly, Elai Davicioni, Anthony E Sisk, Wayne G Brisbane, Leonard S Marks

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03503643 (Cryoablation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03503643 completednot on this map

Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA)

TypeobservationalSponsorJonsson Comprehensive Cancer CenterRan2017 to 2025Enrolled354ConditionsProstate Cancer, Prostate Adenocarcinoma, Prostate DiseaseArmsHemigland Cryoablation
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adam B WeinerDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-1912-042X
James A ProudfootVeracyte, Inc. San Diego, CA.
Mamdouh AkerDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Michelle CardenasDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Samantha GonzalezDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-1156-0620
Eileen KellyVeracyte, Inc. San Diego, CA.
Elai DavicioniVeracyte, Inc. San Diego, CA.
Anthony E SiskDepartment of Pathology, University of California- Los Angeles, Los Angeles, CA.
Wayne G BrisbaneDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-0470-5262
Leonard S MarksDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-7910-179X

Funding

Prospective Assessment of Image Registration for the Diagnosis of Prostate CancerR01CA195505 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2015 to 2016
$705k
NCI NIH HHS R01 CA195505
6 · The paper itself

Abstract

purposeA biomarker to help predict outcomes after prostate cancer (PCa) focal therapy would be of considerable interest. We sought to assess the association between treatment failure after focal therapy and the Decipher score, a tumor-based genomic classifier (GC). MATERIALS AND

methodsWe performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland cryoablation of the prostate (2017-2021; n = 108). Pretreatment biopsy tissue was subjected to transcriptomic profiling to generate GC scores. The primary outcome was the association between GC-low (<0.45) versus GC-high (≥0.45) and in-field recurrence (GG ≥2) on magnetic resonance imaging-guided biopsy 6 months post-treatment, evaluated using multivariable logistic regression.

resultsIn the GC-high group (n = 37), treatment failure occurred in 17 patients (46%). In the GC-low group (n = 71), treatment failure occurred in 15 patients (21%). These differences were statistically significant (odds ratio [OR], 2.61 [95% CI, 1.05 to 6.51];

conclusionIn patients with PCa otherwise suitable for management with focal therapy, a high GC score (≥0.45) was independently associated with treatment failure. A GC score derived from diagnostic biopsy can be used to help predict focal therapy outcomes.

Indexed as

Biomarkers, TumorProstatic NeoplasmsAgedCryosurgeryGenomicsHumansMagnetic Resonance ImagingMaleMiddle AgedTreatment FailureBiomarkers, Tumor

Identifiers

PMID40961406
PMCPMC12445177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.